Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged phosphatidylinositol 3-kinase α (PI3Kα) (E545K mutant) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Tessellate Bio BV has announced it is collaborating with CMRI (Children’s Medical Research Institute) and Omico (Australian Genomic Cancer Medicine Centre) to advance the understanding of the prevalence of alternative lengthening of telomeres (ALT) across tumor types and the genetic factors involved.
China’s National Medical Products Administration (NMPA) has accepted NDAs for Innovent Biologics Inc.’s IL-23p19 antibody picankibart to treat moderate to severe plaque psoriasis, and Lepu Biopharma’s antibody-drug conjugate MRG-003, to treat recurrent or metastatic nasopharyngeal cancer.
Cancer Research Technology Ltd. and My-T Bio Ltd. have jointly developed biarylamide derivatives acting as membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1) inhibitors with potential for the treatment of cancer.
Work at Axcynsis Therapeutics Pte. Ltd. has led to the creation of antibody-drug conjugates (ADCs) comprising antibodies covalently linked to ecteinascidin and lurbinectedin derivatives through a linker; they are reported to be useful for the treatment of cancer.
Vividion Therapeutics Inc. has patented 2-azaspiro[3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of cancer.
Insilico Medicine Inc. has synthesized cyclin-dependent kinase 8/19 (CDK8/19) dual inhibitors reported to be useful for the treatment of autoimmune disease and cancer.
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based on a previously described PD-L1 inhibitor, and systematic screening of ligands and linkers, combined with structure-activity relationship analysis of the degraders, led to the identification of compounds [I] and [II] as the most active candidates.
RSS
